Julia Debik1, Hartmut Schäfer2, Trygve Andreassen3, Feng Wang3,4, Fang Fang2, Claire Cannet2, Manfred Spraul2, Tone F Bathen3,5, Guro F Giskeødegård6,7,8. 1. Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway. julia.b.debik@ntnu.no. 2. Bruker BioSpin AIC Division, Ettlingen, Germany. 3. Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway. 4. Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 5. Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 6. Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. guro.giskeodegard@ntnu.no. 7. Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. guro.giskeodegard@ntnu.no. 8. K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway. guro.giskeodegard@ntnu.no.
Abstract
BACKGROUND: The aim of this study was to gain an increased understanding of the aetiology of breast cancer, by investigating possible associations between serum lipoprotein subfractions and metabolites and the long-term risk of developing the disease. METHODS: From a cohort of 65,200 participants within the Trøndelag Health Study (HUNT study), we identified all women who developed breast cancer within a 22-year follow-up period. Using nuclear magnetic resonance (NMR) spectroscopy, 28 metabolites and 89 lipoprotein subfractions were quantified from prediagnostic serum samples of future breast cancer patients and matching controls (n = 1199 case-control pairs). RESULTS: Among premenopausal women (554 cases) 14 lipoprotein subfractions were associated with long-term breast cancer risk. In specific, different subfractions of VLDL particles (in particular VLDL-2, VLDL-3 and VLDL-4) were inversely associated with breast cancer. In addition, inverse associations were detected for total serum triglyceride levels and HDL-4 triglycerides. No significant association was found in postmenopausal women. CONCLUSIONS: We identified several associations between lipoprotein subfractions and long-term risk of breast cancer in premenopausal women. Inverse associations between several VLDL subfractions and breast cancer risk were found, revealing an altered metabolism in the endogenous lipid pathway many years prior to a breast cancer diagnosis.
BACKGROUND: The aim of this study was to gain an increased understanding of the aetiology of breast cancer, by investigating possible associations between serum lipoprotein subfractions and metabolites and the long-term risk of developing the disease. METHODS: From a cohort of 65,200 participants within the Trøndelag Health Study (HUNT study), we identified all women who developed breast cancer within a 22-year follow-up period. Using nuclear magnetic resonance (NMR) spectroscopy, 28 metabolites and 89 lipoprotein subfractions were quantified from prediagnostic serum samples of future breast cancer patients and matching controls (n = 1199 case-control pairs). RESULTS: Among premenopausal women (554 cases) 14 lipoprotein subfractions were associated with long-term breast cancer risk. In specific, different subfractions of VLDL particles (in particular VLDL-2, VLDL-3 and VLDL-4) were inversely associated with breast cancer. In addition, inverse associations were detected for total serum triglyceride levels and HDL-4 triglycerides. No significant association was found in postmenopausal women. CONCLUSIONS: We identified several associations between lipoprotein subfractions and long-term risk of breast cancer in premenopausal women. Inverse associations between several VLDL subfractions and breast cancer risk were found, revealing an altered metabolism in the endogenous lipid pathway many years prior to a breast cancer diagnosis.
Authors: R Kaaks; S Rinaldi; T J Key; F Berrino; P H M Peeters; C Biessy; L Dossus; A Lukanova; S Bingham; K-T Khaw; N E Allen; H B Bueno-de-Mesquita; C H van Gils; D Grobbee; H Boeing; P H Lahmann; G Nagel; J Chang-Claude; F Clavel-Chapelon; A Fournier; A Thiébaut; C A González; J R Quirós; M-J Tormo; E Ardanaz; P Amiano; V Krogh; D Palli; S Panico; R Tumino; P Vineis; A Trichopoulou; V Kalapothaki; D Trichopoulos; P Ferrari; T Norat; R Saracci; E Riboli Journal: Endocr Relat Cancer Date: 2005-12 Impact factor: 5.678
Authors: Xuehong Zhang; Shelley S Tworoger; A Heather Eliassen; Susan E Hankinson Journal: Breast Cancer Res Treat Date: 2013-01-03 Impact factor: 4.872
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: T J Key; P N Appleby; G K Reeves; A W Roddam; K J Helzlsouer; A J Alberg; D E Rollison; J F Dorgan; L A Brinton; K Overvad; R Kaaks; A Trichopoulou; F Clavel-Chapelon; S Panico; E J Duell; P H M Peeters; S Rinaldi; I S Fentiman; M Dowsett; J Manjer; P Lenner; G Hallmans; L Baglietto; D R English; G G Giles; J L Hopper; G Severi; H A Morris; S E Hankinson; S S Tworoger; K Koenig; A Zeleniuch-Jacquotte; A A Arslan; P Toniolo; R E Shore; V Krogh; A Micheli; F Berrino; E Barrett-Connor; G A Laughlin; M Kabuto; S Akiba; R G Stevens; K Neriishi; C E Land; J A Cauley; Li Yung Lui; Steven R Cummings; M J Gunter; T E Rohan; H D Strickler Journal: Br J Cancer Date: 2011-07-19 Impact factor: 7.640